To determine the molecular basis for the insensitivity of rat ␣ IIb ␤ 3 to inhibition by RGD-containing peptides, hybrids of human and rat ␣ IIb ␤ 3 and chimeras of ␣ IIb ␤ 3 in which ␣ IIb was composed of portions of human and rat ␣ IIb were expressed in Chinese hamster ovary cells and B lymphocytes, and the ability of the tetrapeptide RGDS to inhibit fibrinogen binding to the various forms of ␣ IIb ␤ 3 was measured. These measurements indicated that sequences regulating the sensitivity of ␣ IIb ␤ 3 to RGDS are located in the seven amino-terminal repeats of ␣ IIb . Moreover, replacing the first three or four (but not the first two) repeats of rat ␣ IIb with the corresponding human sequences enhanced sensitivity to RGDS, whereas replacing the first two or three repeats of human ␣ IIb with the corresponding rat sequences had little or no effect. Nevertheless, RGDS bound to Chinese hamster ovary cells expressing ␣ IIb ␤ 3 regardless whether the ␣ IIb in the heterodimers was human, rat, or a rat-human chimera. These results indicate that the sequences determining the sensitivity of ␣ IIb ␤ 3 to RGD-containing peptides are located in the third and fourth amino-terminal repeats of ␣ IIb . Because RGDS binds to both human and rat ␣ IIb ␤ 3 , the results suggest that differences in RGDS sensitivity result from differences in the allosteric changes induced in these repeats following RGDS binding.
Ligand binding to integrins initiates intracellular signals that are crucial for cellular growth and differentiation (1) . Conversely, many cells regulate the ability of their integrins to recognize ligands. The prototypic example of integrin regulation is the platelet integrin ␣ IIb ␤ 3 (2) . In unstimulated platelets, ␣ IIb ␤ 3 is inactive; but following platelet stimulation by agonists such as ADP and thrombin, ␣ IIb ␤ 3 assumes a conformation in which it is able to bind macromolecular ligands such as fibrinogen and von Willebrand factor. Because ligand binding to ␣ IIb ␤ 3 is a prerequisite for platelet aggregation, regulating the affinity of ␣ IIb ␤ 3 for ligands assures that only stimulated platelets aggregate.
The major ligand for ␣ IIb ␤ 3 in plasma is fibrinogen. Three portions of the fibrinogen molecule (the carboxyl terminus of the fibrinogen ␥-chain (3) and two Arg-Gly-Asp (RGD) motifs located in the fibrinogen ␣-chain (4)) have been proposed to be sites that mediate fibrinogen binding to ␣ IIb ␤ 3 . However, ultrastructural examination of fibrinogen bound to ␣ IIb ␤ 3 (5) and measurements of fibrinogen binding to ␣ IIb ␤ 3 using fibrinogens containing mutated RGD or ␥-chain sequences (6) indicate that it is the ␥-chain sequences that mediate fibrinogen binding. Nonetheless, RGD-containing disintegrins and synthetic compounds based on the RGD motif are effective ␣ IIb ␤ 3 antagonists (7), implying that they either directly or indirectly affect the ␥-chain-binding site when they bind to ␣ IIb ␤ 3 . Ligands appear to bind to ␣ IIb ␤ 3 by interacting with the amino-terminal portion of ␤ 3 (8) , although the specific residues involved are not known. A region of ␤ 3 encoded by the fourth and fifth exons of the ␤ 3 gene that encompasses amino acids 95-223 has been implicated in ligand binding (9) . Moreover, chemical cross-linking experiments have suggested that RGDcontaining peptides bind to ␤ 3 in the vicinity of amino acids 109 -171 (10) . It is noteworthy that this region of ␤ 3 contains an array of oxygenated residues whose three-dimensional structure may resemble that of the ligand-binding I domains that are present in several integrin ␣-subunits (11) . In addition, overlapping peptides corresponding to ␤ 3 amino acids 211-222 inhibit fibrinogen binding to purified ␣ IIb ␤ 3 , suggesting that this stretch of residues represents a portion of the fibrinogenbinding site (12, 13) . There is also evidence that more distal portions of ␤ 3 may be involved in fibrinogen binding because a naturally occurring Leu 262 3 Pro mutation prevents ␣ IIb ␤ 3 binding to immobilized fibrinogen (14) .
Ligand binding to ␣ IIb ␤ 3 also appears to involve the aminoterminal third of ␣ IIb (15) . Chemical cross-linking experiments suggest that the carboxyl terminus of the fibrinogen ␥-chain binds to ␣ IIb in the vicinity of amino acids 294 -314 (16), a suggestion supported by the ability of a peptide corresponding to ␣ IIb residues 300 -312 to inhibit platelet adhesion to fibrinogen (17) . In addition, there are a number of reports of naturally occurring and laboratory-induced mutations involving amino acids located between ␣ IIb residues 183 and 224 that impair ␣ IIb ␤ 3 function, suggesting that this portion of ␣ IIb binds to ligands as well (18 -21) .
Although fibrinogen binding to ␣ IIb ␤ 3 on the platelets of all mammalian species is required for platelet aggregation, there are substantial differences in the ability of RGD-containing peptides to inhibit the process. For example, fibrinogen binding to rabbit and rat platelets is relatively insensitive to inhibition by RGD-containing peptides (22, 23) . To gain an understanding of the molecular basis for the insensitivity of rat ␣ IIb ␤ 3 to RGD-containing peptides, we measured the effect of the tetrapeptide Arg-Gly-Asp-Ser (RGDS) on fibrinogen binding to chimeric ␣ IIb ␤ 3 molecules composed of portions of the rat and human proteins. We found that the sequences determining the sensitivity or resistance of ␣ IIb ␤ 3 to inhibition by RGDS are located in the third and fourth repeats of the amino-terminal portion of ␣ IIb . Moreover, because we also found that RGDS bound to ␣ IIb ␤ 3 regardless of whether the heterodimer contained human or rat subunits, our results imply that RGDS impairs fibrinogen binding to ␣ IIb ␤ 3 by inducing an allosteric change in the third and fourth repeats of ␣ IIb . They also suggest that a conformational change in these repeats may be required for the fibrinogen binding to ␣ IIb ␤ 3 that occurs on agoniststimulated platelets.
EXPERIMENTAL PROCEDURES
Measurement of Platelet Aggregation-Platelet-rich plasma was prepared from blood anticoagulated with 0.1 volume of 0.13 M sodium citrate, obtained from normal human volunteers by venipuncture and from anesthetized rats by puncture of the exposed abdominal aorta. Platelets were isolated from the platelet-rich plasma by gel filtration on Sepharose 2B (Amersham Pharmacia Biotech) using elution buffer containing 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl 2 , 5.6 mM glucose, 0.35 mg/ml bovine serum albumin, 3.3 mM NaH 2 PO 4 , and 4 mM Hepes (pH 7.4) as previously described (24) . Turbidometric measurements of ADPstimulated platelet aggregation were made in a Chrono-Log Lumi dual aggregometer. Platelet suspensions were supplemented with either human or rat fibrinogen (Sigma) at a final concentration of 200 g/ml, with 1 mM CaCl 2 , and with various concentrations of RGDS (Sigma) or the less active control tetrapeptide Arg-Gly-Glu-Ser (RGES; Sigma) prior to adding ADP.
Measurement of Fibrinogen Binding to Human and Rat
PlateletsFibrinogen binding to gel-filtered human and rat platelets was measured using 125 I-labeled fibrinogen as previously described (24) . Briefly, 0.5-ml aliquots of Ϸ5 ϫ 10 7 gel-filtered platelets were mixed with 200 g/ml 125 I-fibrinogen (Enzyme Research Laboratories), 0.5 mM CaCl 2 , and 10 M ADP. Following a 5-min incubation at 37°C without stirring, the platelets were sedimented through silicone oil in an Eppendorf centrifuge (Brinkmann Instruments). The tips of the centrifuge tubes containing the pelleted platelets were amputated and counted for 125 I. Nonspecific fibrinogen binding was determined by including a 15-fold excess of unlabeled fibrinogen in the assay. The dissociation constants (K d ) for human and rat ␣ IIb ␤ 3 for fibrinogen were obtained by Scatchard analysis of the fibrinogen binding data.
Construction of Chimeric Human-Rat ␣ IIb Subunits-Full-length cDNAs for human and rat ␣ IIb and a full-length cDNA for human ␤ 3 were used in selected experiments (25) (26) (27) (28) . A nearly full-length rat ␤ 3 cDNA was completed by inserting the sequences corresponding to the signal peptide and the first 31 amino acids of human ␤ 3 (21, 29) . The amino-terminal region of mature ␤ 3 is highly conserved; for example, human and Xenopus ␤ 3 cDNAs differ by only nine amino acids in this region (30) .
cDNAs encoding chimeras of ␣ IIb in which the amino-terminal halves of human and rat ␣ IIb were exchanged were constructed by swapping homologous ClaI/NheI 5Ј-fragments of human and rat ␣ IIb cDNAs (28) . cDNAs encoding ␣ IIb chimeras containing smaller segments of rat and human ␣ IIb were constructed using a polymerase chain reaction-based site-directed mutagenesis protocol described previously (21) . Briefly, using either a human or rat ␣ IIb cDNA template, the 3Ј-portion of the targeted sequence was amplified using one of the sense primers shown below and the appropriate antisense primer 3Ј to the ClaI site. Similarly, the 5Ј-portion was amplified using the appropriate ␣ IIb cDNA template, a primer complementary to one of the sense primers shown below, and a T7 primer. The 5Ј-and 3Ј-polymerase chain reaction products were then purified on agarose gels after separation from the templates. A third polymerase chain reaction was performed using the two first-round amplified products, the T7 primer, and the appropriate primer 3Ј to the ClaI site in the template. The product was double-digested with ClaI and NheI and subcloned into either a human or rat ␣ IIb cDNA that had previously been inserted into the expression plasmid pcDNA3.1 (Invitrogen). Selected clones were sequenced to ensure the fidelity of the desired nucleotide sequence. The nomenclature used to identify the various chimeras is based on the presence of seven tandem repeats in the amino-terminal half of ␣ IIb (31 . cDNAs encoding human ␤ 3 and either human or rat ␣ IIb were subcloned into pcDNA3.1(ϩ)-Zeo and pcDNA3.1(ϩ)-Neo, respectively, and were introduced into the CHO cells using FUGENE 6 (Roche Molecular Biochemicals) according to the manufacturer's instructions. Two days after transfection, the cells were transferred to selection medium containing 500 g/ml G418 (Life Technologies, Inc.) and 300 g/ml Zeocin (Invitrogen). After 3 weeks of selection, ␣ IIb ␤ 3 expression was assessed by flow cytometry using P34, a mAb that recognizes both rat and human ␣ IIb ␤ 3 (a gift from Dr. H. Miyazaki, Kirin Brewery, Gunma, Japan). The cells were then sorted by fluorescence-activated cell sorting to obtain cell lines expressing high levels of ␣ IIb ␤ 3 as previously described (21) . Fibrinogen Binding to CHO Cells Expressing ␣ IIb ␤ 3 -To measure fibrinogen binding to ␣ IIb ␤ 3 on the transfected CHO cells, purified human fibrinogen was labeled with fluorescein isothiocyanate (FITC) using a Calbiochem FITC labeling kit as described by the manufacturer. Fibrinogen labeled in this manner was monomeric as assessed by gel-filtration chromatography, supported platelet aggregation as well as unlabeled fibrinogen, and was 95% clottable with thrombin (32). 1.5 ϫ 10 5 CHO cells, suspended in 100 l of 10 mM sodium phosphate buffer (pH 7.4) containing 137 mM NaCl, 1 mM CaCl 2 , and 1% bovine serum albumin, were then incubated with 200 g/ml FITC-fibrinogen and 5 mM dithiothreitol (DTT) for 30 min at 37°C (33, 34) . The cells were washed once with the suspension buffer and fixed with 0.37% formalin. The amount of FITC-fibrinogen bound was determined by flow cytometry as described previously (21) . Specific fibrinogen binding represented the difference in fluorescence of transfected and untransfected cells incubated with FITC-fibrinogen in the presence of DTT minus the fluorescence of transfected cells incubated with FITC-fibrinogen in the absence of DTT. The ability of RGDS to inhibit fibrinogen binding was determined by adding increasing concentrations of the tetrapeptide to the 30-min incubation.
Adhesion of B Lymphocytes Expressing ␣ IIb ␤ 3 to Immobilized Fibrinogen-␣ IIb and ␤ 3 were expressed in human B lymphocytes as previously described (35) . Briefly, pREP vectors containing rat or human ␣ IIb and ␤ 3 cDNAs were introduced into 7.5 ϫ 10 6 GM1500 B lymphocytes by electroporation (250 V and 960 microfarads). Stable transfectants were selected using G418 and hygromycin, and the amount of ␣ IIb ␤ 3 on the lymphocyte surface was quantified by flow cytometry using mAb P34. To measure ␣ IIb ␤ 3 -mediated lymphocyte adherence to fibrinogen, the wells of Immulon-2 flat-bottom microtiter plates (Dynatech Laboratories Inc.) were coated with 50 g/ml purified human fibrinogen in 50 mM NaHCO 3 buffer (pH 8.0) containing 150 mM NaCl. Unoccupied protein-binding sites on the wells were blocked with 5 mg/ml bovine serum albumin dissolved in the same buffer. 1.5 ϫ 10 5 B lymphocytes, metabolically labeled overnight with [ 35 S]methionine, were suspended in 100 l of 50 mM Tris-HCl buffer (pH 7.4) containing 150 mM NaCl, 0.5 mM CaCl 2 , 0.1% glucose, and 1% bovine serum albumin and added to the protein-coated wells, in either the presence or absence of 200 ng/ml phorbol myristate acetate. Following incubation at 37°C for 30 min without agitation, the plates were washed four times with the lymphocyte suspension buffer, and adherent cells were dissolved using 2% SDS. The SDS solutions were then counted for 35 S in a liquid scintillation counter. The ability of RGDS to inhibit lymphocyte adhesion to immobilized fibrinogen was determined by adding increasing concentrations of the tetrapeptide to the 30-min incubation.
Induction of mAb Binding to ␤ 3 by RGDS-To measure the RGDSinduced binding of the conformation-specific mAb 10-758 to human ␤ 3 (36), 1.5 ϫ 10 5 CHO cells expressing human ␣ IIb ␤ 3 and hybrids of rat ␣ IIb and human ␤ 3 were incubated with 0.3 mM RGDS and a 1:100 dilution of mAb 10-758 for 30 min at 37°C. The cells were then washed once and incubated with a 1:10 dilution of FITC-labeled goat anti-mouse IgG for an additional 30 min. Antibody binding was detected using flow cytometry.
RESULTS

Effect of RGDS on the ADP-stimulated Aggregation of Human and Rat
Platelets-To confirm the reported insensitivity of rat platelets to the inhibitory effects of RGD-containing peptides (22), we compared the ability of the tetrapeptide RGDS to inhibit the ADP-stimulated aggregation of gel-filtered human and rat platelets. Although neither human nor rat platelets aggregated in the absence of added fibrinogen (data not shown), ADP-stimulated platelets of both species aggregated readily in the presence of either human or rat fibrinogen (Fig. 1) . Furthermore, whereas the tetrapeptide RGES had no effect on the aggregation of platelets of either species, the aggregation of human platelets was partially inhibited by 10 M RGDS and completely inhibited by 100 M RGDS. In contrast, concentrations of RGDS as great as 1 mM had no effect on the aggregation of rat platelets. Thus, these experiments confirm the difference in sensitivity of human and rat platelets to RGD-containing peptides and indicate that this difference is due to a difference between human and rat platelets and not to a difference between human and rat fibrinogen.
One explanation for the insensitivity of rat platelets to RGDS is simply that the affinity of ␣ IIb ␤ 3 on rat platelets for fibrinogen is greater than that of ␣ IIb ␤ 3 on human platelets. To address this possibility, we measured the affinity of ␣ IIb ␤ 3 on human and rat platelets using 125 I-labeled fibrinogen (24) . We found that the K d for fibrinogen binding to ␣ IIb ␤ 3 on human platelets was (1.32 Ϯ 0.12) ϫ 10 Ϫ7 (n ϭ 21), compared with a K d of (2.31 Ϯ 0.45) ϫ 10 Ϫ7 (n ϭ 3) for fibrinogen binding to ␣ IIb ␤ 3 on rat platelets. Thus, these measurements indicate that a difference in the affinity of human and rat ␣ IIb ␤ 3 for fibrinogen cannot account for the difference in sensitivity of human and rat platelets to RGDS.
Effect of RGDS on Fibrinogen Binding to Human-Rat ␣ IIb ␤ 3 Hybrids Expressed in CHO Cells-We next sought a molecular basis for the difference in sensitivity of human and rat platelets to RGDS by expressing ␣ IIb ␤ 3 heterodimers composed of human and rat subunits in CHO cells. As shown by the flow cytometry histograms in Fig. 2 , comparable amounts of each of the four possible combinations of human and rat ␣ IIb and ␤ 3 were expressed on the CHO cell surface.
Because ␣ IIb ␤ 3 expressed in CHO cells cannot be activated by cellular agonists, ligand binding is usually induced using "activating" mAbs (37) . These antibodies generally do not bind to rat ␣ IIb ␤ 3 . Consequently, we induced fibrinogen binding to ␣ IIb ␤ 3 in our CHO cell lines by incubating the cells with DTT, based on previous reports that DTT induces fibrinogen binding to ␣ IIb ␤ 3 on platelets (33, 34) . To confirm that the fibrinogen binding induced by DTT is indeed comparable to that induced by activating mAbs, we incubated CHO cells expressing human ␣ IIb ␤ 3 with 5 mM DTT and with the activating mAb PT25-2 and measured FITC-fibrinogen binding to the incubated cells using flow cytometry. As shown by the histograms in Fig. 3 , fibrinogen binding induced by DTT and mAb PT25-2 was indistinguishable. Moreover, the fibrinogen binding induced by either agent was inhibited by the ␣ IIb ␤ 3 -specific mAb A2A9, confirming that the fibrinogen was bound to ␣ IIb ␤ 3 . The effect of RGDS on fibrinogen binding to the cell lines shown in Fig. 2 was studied by adding increasing concentrations of the tetrapeptide to the fibrinogen binding assays. The results of these experiments are shown in Fig. 4 . As expected, fibrinogen binding to cells expressing human ␣ IIb ␤ 3 was relatively sensitive to inhibition by RGDS, whereas fibrinogen binding to cells expressing rat ␣ IIb ␤ 3 was relatively resistant. However, to our surprise, based on the observation that RGDcontaining peptides cross-link to the amino terminus of ␤ 3 (10), we found that fibrinogen binding to cells expressing ␣ IIb ␤ 3 containing a rat ␣-subunit and a human ␤-subunit was resistant to RGDS, whereas fibrinogen binding to cells expressing ␣ IIb ␤ 3 containing a human ␣-subunit and a rat ␤-subunit was sensitive. The IC 50 values (concentrations of RGDS that inhibited fibrinogen binding by 50%) for RGDS, calculated from semilog plots of the binding data, were 1.65 and 2.07 mM for cells expressing rat ␣ IIb ␤ 3 and rat ␣ IIb /human ␤ 3 , compared with 0.04 and 0.01 mM for cells expressing human ␣ IIb ␤ 3 and human ␣ IIb /rat ␤ 3 (Table I) , respectively.
Effect of RGDS on the Adhesion of B Lymphocytes Expressing ␣ IIb ␤ 3 to Immobilized Fibrinogen-To rule out the possibility that the observed differences in sensitivity to RGDS were due to differences in the response of human and rat ␣ IIb to DTT, we expressed the four combinations of human and rat ␣ IIb and ␤ 3 in the B lymphocyte cell line GM1500 (35) . Flow cytometry of the transfected cells using mAb P34 indicated that each of the combinations of human and rat ␣ IIb and ␤ 3 was expressed to a comparable extent on the lymphocyte surface (data not shown). We then measured the effect of RGDS on phorbol 12-myristate 13-acetate-stimulated lymphocyte adhesion to immobilized fibrinogen. As shown in Fig. 5 , we found that lymphocytes expressing ␣ IIb ␤ 3 heterodimers containing an ␣-subunit of human origin were Ϸ20-fold more sensitive to the inhibitory effect of RGDS than lymphocytes expressing heterodimers containing an ␣-subunit of rat origin. Thus, these experiments confirm that the difference in sensitivity of human and rat ␣ IIb ␤ 3 to RGD-containing peptides can be attributed to structural differences between human and rat ␣ IIb .
Localization of the ␣ IIb Regions Regulating Sensitivity to RGDS Using Human-Rat ␣ IIb Chimeras-The amino-terminal portion of ␣ IIb consists of seven tandem repeats, each of which contains ϳ60 amino acids (31) . To localize the sites in ␣ IIb that regulate sensitivity to RGDS, we exchanged the amino-terminal repeats of rat ␣ IIb for the human repeats and vice versa, making use of a conserved ClaI restriction site. The ␣ IIb chimeras were then coexpressed with human ␤ 3 in CHO cells, and the ability of RGDS to inhibit the binding of FITC-fibrinogen to the chimeras was tested. As shown in Fig. 6 , chimeras in which the seven amino-terminal repeats of ␣ IIb were of human origin were sensitive to RGDS, whereas chimeras in which the seven amino-terminal repeats were of rat origin were resistant. Thus, these experiments indicate that the sequences regulating the sensitivity of ␣ IIb ␤ 3 to RGDS are located in the seven aminoterminal repeats of ␣ IIb . 
FIG. 3. Comparison of mAb PT25-2-induced and DTT-induced FITC-fibrinogen binding to CHO cells expressing human ␣
Identification of Specific Regions of the Amino Terminus of ␣ IIb
That Regulate Sensitivity to RGDS-To further localize the sequences that regulate the sensitivity of ␣IIb ␤ 3 to RGDS, we replaced the first two, three, and four amino-terminal repeats of rat ␣ IIb with the corresponding human sequences. The resulting chimeric ␣-subunits were coexpressed with human ␤ 3 in CHO cells, and the ability of RGDS to inhibit FITC-fibrinogen binding to each cell line was measured. As shown in Fig.  7A , when the first four repeats of rat ␣ IIb were replaced by the human sequences, the resulting ␣ IIb ␤ 3 heterodimer was sensitive to RGDS. In contrast, when only the first two repeats were of human origin, the ␣ IIb ␤ 3 chimera was resistant. A chimera in which the first three repeats were of human origin was of intermediate sensitivity. Thus, these data indicate that sequences regulating the response of ␣ IIb ␤ 3 to RGDS are located in the third and fourth amino-terminal repeats of ␣ IIb .
To confirm this conclusion, we made the reciprocal exchanges. However, although human ␣ IIb in which the first and second repeats and the first through third repeats were replaced by the corresponding rat sequences readily coexpressed with human ␤ 3 on the CHO cell surface, ␣ IIb in which the first through fourth repeats were of rat origin was never expressed to a level sufficient to measure fibrinogen binding. Nonetheless, as shown in Fig. 7B , replacing the first and second human repeats with the corresponding rat sequence had no effect on the sensitivity of ␣ IIb ␤ 3 to RGDS, and a chimera in which the first through third repeats were exchanged was only slightly less sensitive. Thus, these results are consistent with those shown in Fig. 7A .
The IC 50 values for RGDS inhibition of fibrinogen binding to the various cell lines, as well as a relative RGDS resistance index derived by normalizing the IC 50 values to that for human ␣ IIb ␤ 3 , are shown in Table I . This analysis verifies that the locus for sensitivity to RGDS is located in ␣ IIb and that the relevant sequences are present in its third and fourth aminoterminal repeats.
Induction of mAb Binding to ␤ 3 by RGDS-Based on these data, there are two possible ways in RGDS could inhibit fibrinogen binding to ␣IIb␤ 3 . First, it is possible that RGDS binds to the third and fourth amino-terminal repeats of ␣ IIb and directly competes with fibrinogen for binding to this site. Second, it is possible that RGDS binds elsewhere in ␣ IIb ␤ 3 and exerts an allosteric effect on the third and fourth amino-terminal repeats of ␣IIb, thereby inhibiting fibrinogen binding. Binding of RGDbased peptides and peptidomimetics to ␣ IIb ␤ 3 has been shown to induce the expression of epitopes for a number of anti-␣ IIb and anti-␤ 3 mAbs (36) . Therefore, to differentiate between the two possibilities discussed above, we measured the ability of RGDS to induce the binding of the human ␤ 3 -specific mAb 10-758 to RGDS-sensitive human ␣ IIb ␤ 3 , to RGDS-resistant rat ␣ IIb /human ␤ 3 , and to RGDS-resistant ␣ IIb ␤ 3 in which the amino-terminal half of ␣ IIb was of rat origin. As shown in Fig. 8, 0 .3 mM RGDS induced mAb 10-758 binding to each form of ␣ IIb ␤ 3 . We conclude from these data that RGDS bound to each form of ␣ IIb ␤ 3 , a result consistent with the possibility that RGDS inhibits fibrinogen binding to ␣ IIb ␤ 3 by inducing an allosteric change in the third and fourth amino-terminal ␣ IIb repeats.
DISCUSSION
Although fibrinogen appears to bind to ␣ IIb ␤ 3 exclusively via sequences located at the carboxyl-terminal end of the fibrinogen ␥-chain (5, 6), peptides containing an RGD motif are competitive inhibitors of fibrinogen binding to ␣ IIb ␤ 3 (4). Moreover, despite chemical cross-linking experiments suggesting that the ␥-chain and RGD-containing peptides bind to different subunits of the ␣ IIb ␤ 3 heterodimer (16, 38) , competitive binding measurements indicate that the peptides bind to ␣ IIb ␤ 3 in a mutually exclusive manner (39) , implying either that the peptides bind to same site or that the binding sites interact allosterically. Hu et al. (40) , using plasmon resonance spectroscopy to study the effect of RGD ligands on fibrinogen binding to ␣ IIb ␤ 3 , concluded that fibrinogen and RGD ligands bind to separate sites on ␣ IIb ␤ 3 , but suggested that there is an allosteric relationship between the two. Using chimeras of RGDinsensitive rat ␣ IIb ␤ 3 and RGD-sensitive human ␣ IIb ␤ 3 , we found that sensitivity to the inhibitory effects of the tetrapeptide RGDS was determined by the origin of the third and fourth amino-terminal repeats of ␣ IIb . We also found little difference in the affinity of ␣ IIb ␤ 3 on human and rat platelets for fibrinogen. Thus, our data suggest that rather than directly affecting fibrinogen binding, species differences in the third and fourth ␣ IIb repeats affect an allosteric change that regulates fibrinogen binding to ␣ IIb ␤ 3 .
Ligand binding to ␣ IIb ␤ 3 is thought to involve regions located in the amino-terminal portions of both ␣ IIb and ␤ 3 (8) , although much of this evidence is indirect. The ␤ 3 region encompasses amino acids 95-223 (9) and includes the RGD-cross-linking site located in the vicinity of amino acids 109 -171 (38) as well as an array of oxygenated residues whose fold may resemble that of the ligand-binding metal ion-dependent adhesion sites (MIDAS) present in integrin I domains (11) . It is noteworthy that the deleterious effect of an Arg 214 3 Trp mutation, located in the midst of this sequence, can be reversed by exposing ␣ IIb ␤ 3 to DTT, suggesting that the presence of Trp at residue 214 does not prevent fibrinogen binding to ␣ IIb ␤ 3 directly, but rather obscures the fibrinogen-binding site (41) .
It is also noteworthy that the location of the binding site for RGD-containing peptides in integrins is uncertain, and there is evidence for binding sites in both ␣-and ␤-subunits. For example, proteins corresponding to the fourth through seventh amino-terminal repeats of ␣ 5 and ␣ IIb bind to fibronectin III fragment-(8 -10) and to fibrinogen, respectively, in an RGDdependent manner (42, 43) . Conversely, experiments using chemical and photoaffinity cross-linking, site-directed mutagenesis, synthetic integrin and RGD-containing peptides, and mAbs have identified regions in the amino-terminal portion of ␤ 1 -and ␤ 3 -subunits that recognize the RGD motif (11, 38, 44 -46) . Based on these observations, one possible explanation for our results is simply that RGDS does not bind to either rat ␣ IIb or rat ␤ 3 . However, we found that first, the sensitivity of ␣ IIb ␤ 3 composed of human subunits or of a human ␣-subunit and rat ␤-subunit to RGDS was equivalent, and second, binding of mAb 10-758 to human ␤ 3 was induced by RGDS to an equal extent regardless of whether ␣ IIb was human, rat, or a human-rat chimera. Thus, our data imply that RGDS binds to both human and rat ␣ IIb ␤ 3 and that differences in its inhibitory potency are due to differences in allosteric events that follow RGDS binding.
The portion of ␣ IIb implicated in ligand binding has also been localized to the amino-terminal third of the molecule (15) and includes the fibrinogen ␥-chain peptide-cross-linking site at amino acids 294 -314 (16) . In addition, a number of naturally occurring and laboratory-induced mutations involving amino acids 145, 183, 184, 189, 190, 191, 193 , and 224 have been described that impair ␣ IIb ␤ 3 function, suggesting that these residues interact with ␣ IIb ␤ 3 ligands (18 -20) . Of note, residues 183-224 are located in the third ␣ IIb repeat (25) . Because our data suggest that the third repeat is involved in the allosteric regulation of fibrinogen binding to ␣ IIb ␤ 3 , it is possible that mutation of the residues listed above interferes with this allosteric change, rather than directly perturbing the fibrinogenbinding site.
The tertiary structure of integrins has yet to be determined. Based on computer modeling, Springer (31) proposed that the amino-terminal portion of integrin ␣-subunits folds into a seven-bladed ␤-propeller configuration, with each of the blades corresponding to a ␤-sheet formed from four anti-parallel ␤-strands located within each of the amino-terminal repeats. that the putative second loop is fully conserved, whereas the first and third loops would be only 50% homologous. Thus, it is possible that amino acid sequence differences between human and rat ␣ IIb in the putative first and third loops could be responsible for the differences in sensitivity of human and rat ␣ IIb ␤ 3 to RGD-containing peptides.
Alterations in the tertiary and/or quaternary structure of integrins regulate their affinity, and possibly their avidity, for ligands. Recent nuclear magnetic resonance spectroscopic and x-ray crystallographic studies of the I domain of ␣ L emphasize the importance of changes in the conformation of the ␣-subunit amino terminus in integrin function (48, 49) . I domains are present in nine integrin ␣-subunits, where they are inserted between the second and third amino-terminal repeats (49) . In ␣ L and ␣ M , ligands such as ICAM-1-3 (intercellular adhesion molecule) bind to a divalent cation-containing MIDAS motif on the upper I domain surface (50 -53) . In the I domain of ␣ L , residues distal to the MIDAS motif, lining a cleft formed by the seventh ␣-helix and the central ␤-sheet, regulate ligand binding to ␣ L ␤ 2 allosterically (49) and constitute the binding site for the ␣ L ␤ 2 inhibitor lovastatin (48) . In addition, mutations in the amino-and carboxyl-terminal linker sequences that connect the I domain to the rest of ␣ L either activate or inactivate I domain function (49) , implying that the changes in I domain conformation that regulate its function are transmitted from the amino-terminal portion of ␣ L to the I domain via these sequences. In the case of ␣ IIb ␤ 3 , agonist-induced changes in tertiary structure are essential for its function (2). Our results indicate that an allosteric change in the third and fourth amino-terminal repeats of ␣ IIb , a portion of ␣ IIb located immediately downstream from the I domain insertion site in I domaincontaining integrins, regulates ligand binding to ␣ IIb ␤ 3 . Thus, by extrapolation, our data suggest that allosteric changes involving the third and fourth ␣-subunit repeats may be a general mechanism by which ligand binding to integrins is regulated.
